Analysts: AstraZeneca's still waiting on a MedImmune benefit; Hamburg goes to bat for FDA's Zohydro approval;

@FierceBiotech: A who's-that of biotechs snag $119M as the IPO market thunders on. More | Follow @FierceBiotech

@JohnCFierce: Leerink's Liang is reducing price target on Aveo. The CMO has left. Execs giving up on a program, credibility is shot. | Follow @JohnCFierce

@DamianFierce: U.K. joins the 'breakthrough' bandwagon with new fast-track program. Story | Follow @DamianFierce

@EmilyMFierce: STAP stem cell scientists criticized by RIKEN for "inappropriate" behavior. No intentional misconduct ID'd so far. Story via LA Times | Follow @EmilyMFierce

> Investors hoping AstraZeneca's ($AZN) costly MedImmune deal will start paying dividends will have to be patient, analysts say, as the company's promising immunotherapies remain years from potential launch. Article

> Facing criticism, FDA Commissioner Margaret Hamburg is defending the agency's approval of Zogenix's ($ZGNX) powerful painkiller Zohydro. News

> Medical device outfit K2M has filed to go public for $100 million. Story

Medical Device News

@FierceMedDev: Another med tech IPO reveal, though K2M hinted in Jan. that this was coming. S-1 | Follow @FierceMedDev

@MarkHFierce: Boston Scientific  isn't giving up on bare metal stents, not by a long shot. Smart move. Story | Follow @MarkHFierce

@MichaelGFierce: Mallinckrodt's U.S. pain drug approval brings Depomed a $10M delivery tech milestone. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Breathing machines made from aquarium pumps could boost preemie survival rates, say researchers at Rice University. Article | Follow @EmilyWFierce

> Stentys touts a revenue bump and cash to burn for its U.S. push. More

> Hologic adds a COO, loses a CFO in a C-level shakeup. Story

> Sorin snatches up a Florida manufacturer's cardiac-lead business for $20M. News

> French surgeons perform closed-heart surgery using a nitinol stent. Item

Pharma News

@FiercePharma: Top-read FP news yesterday: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. Story | Follow @FiercePharma

@TracyStaton: In other India news, Dr. Reddy's pulls 58K bottles of generic Prevacid on microbial contaminationMore from Reuters | Follow @TracyStaton

@EricPFierce: Pharma cargo theft are on the rise again with a 50% bump in truckload rip-offs. News | Follow @EricPFierce

@CarlyHFierce: On that note, here's a story I wrote yesterday about dying cattle (and Merck). Article | Follow @CarlyHFierce

> Under fire, FDA chief Hamburg defends approval of pain pill Zohydro. More

> Gilead's hot-selling Sovaldi draws more patent attacks. Story

> Celgene's superstar Revlimid again dissed by U.K. cost watchdog. News

> FDA cites compounder for making tainted version of KV's Makena. Piece

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.